NCT01309412View on ClinicalTrials.gov

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Siltuximab

5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression

Trial Locations (5)

Unknown

Isehara

Kyoto

Nagoya

Niigata

Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT01309412 - A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter